ScholarX

Browsing by Sevindik, OG[Sevindik, Omur Gokmen]Author

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
전체 가 나 다 라 마 바 사 아 자 차 카 타 파 하

Showing results 1 to 2 of 2

SCIESCOPUS
KEYFORM-008: Coformulated favezelimab and pembrolizumab (MK4280A) versus chemotherapy in relapsed/refractory classical Hodgkin lymphoma.

Lavie, D[Lavie, David]; Timmerman, J[Timmerman, John]; Sanz, RG[Sanz, Ramon Garcia]; Kim, WS[Kim, Won Seog]; Kim, TM[Kim, Tae Min]; Avigdor, A[Avigdor, Abraham]; Dierickx, D[Dierickx, Daan]; Jagadeesh, D[Jagadeesh, Deepa]; Molin, D[Molin, Daniel]; Ozcan, M[Ozcan, Muhit], et al.

ArticleIssue Date2023CitationJOURNAL OF CLINICAL ONCOLOGY, v.41, no.16PublisherLIPPINCOTT WILLIAMS & WILKINS
SCIESCOPUS
Zilovertamab vedotin (MK 2140) in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Early results from the phase 2 waveLINE-004 study.

Ozcan, M[Ozcan, Muhit]; Lee, ST[Lee, Seung Tae]; Mensah, F[Mensah, Felix]; Modi, D[Modi, Dipenkumar]; Fossa, A[Fossa, Alexander]; Kim, WS[Kim, Won Seog]; Paszkiewicz-Kozik, E[Paszkiewicz-Kozik, Ewa]; Sawalha, Y[Sawalha, Yazeed]; Sevindik, OG[Sevindik, Omur Gokmen]; Norasetthada, L[Norasetthada, Lalita], et al.

ArticleIssue Date2023CitationJOURNAL OF CLINICAL ONCOLOGY, v.41, no.16PublisherLIPPINCOTT WILLIAMS & WILKINS
1
STATISTICS
Total View:
Daily View:

RSS_1.0 RSS_2.0 ATOM_1.0

CONTACT US

(03063) 25-2, SUNGKYUNKWAN-RO, JONGNO-GU, SEOUL, KOREA samsunglib@skku.edu

COPYRIGHT © 2021 SUNGKYUNKWAN UNIVERSITY ALL RIGHTS RESERVED.

Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.

BROWSE

한국어